PEDIATRICS Vol. 78 No. 6 December 1986, pp. 1139-1141
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SANTOS, F.
Right arrow Articles by CHAN, J. C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SANTOS, F.
Right arrow Articles by CHAN, J. C. M.

Idiopathic Hypoparathyroidism: A Case Study on the Interactions Between Exogenous, Parathyroid Hormone Infusion and 1,25-Dihydroxyvitamin D

FERNANDO SANTOS MD1 and JAMES C. M. CHAN MD2

1 University of Oviedo and Hospital de la Seguridad Social, Oviedo, Asturias, Spain
2 Department of Pediatrics, Medical College of Virginia and Children's Medical Center, Virginia Commonwealth University, Richmond

Idiopathic hypoparathyroidism is a rare entity which is clinically characterized by episodes of hypocalcemia and hyperphosphatemia with deficient endogenous parathyroid hormone secretion.1,2 Exogenous parathyroid hormone administration elicits the appropriate renal phosphaturic response,3,4 and no associated endocrinopathies have been reported.1,2 Treatment with 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is currently recommended.1,2,5

Responses to exogenous parathyroid hormone infusion consist not only of an increase in urine phosphate excretion but, more definitively, an increase in nephrogenous cyclic adenosine monophosphate (cAMP) production.6 Studies of these parameters in pediatric patients have been reported,3 but little is known about the influence of parathyroid hormone administration on the urine calcium excretion of hypoparathyroidism in children and how the renal response to parathyroid hormone may be modified by the 1,25-(OH)2D3 therapy.